Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment

Synaptic vesicle protein 2A (SV2A), the target of the antiepileptic drug levetiracetam (LEV), is expressed ubiquitously in all synaptic terminals. Its levels decrease in patients and animal models of epilepsy. Thus, changes in SV2A expression could be a critical factor in the response to LEV. Epilep...

詳細記述

書誌詳細

主要な著者:	Itzel Jatziri Contreras-García, Gisela Gómez-Lira, Bryan Víctor Phillips-Farfán, Luz Adriana Pichardo-Macías, Mercedes Edna García-Cruz, Juan Luis Chávez-Pacheco, Julieta G. Mendoza-Torreblanca
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2021-04-01
シリーズ:	Brain Sciences
主題:	SV2A levetiracetam pharmacoresistance VGAT VGLUT temporal lobe epilepsy
オンライン･アクセス:	https://www.mdpi.com/2076-3425/11/5/531
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!